跳至主要内容
临床试验/EUCTR2014-004674-42-GB
EUCTR2014-004674-42-GB进行中(未招募)1 期

A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Gilead Sciences, Inc.0 个研究点目标入组 560 人开始时间: 2015年8月26日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
560

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Subjects must meet all of the following inclusion criteria to be eligible for participation in this Registry.
  • 1. Have previously participated in a Gilead-sponsored chronic hepatitis C study as an adolescent or pediatric subject and received at least one Gilead HCV direct acting antiviral (DAA);
  • 2. Parent or legal guardian able to provide written informed consent OR subject able to provide written informed consent and willing to comply with study requirements as determined by IRB/IEC/local requirements and Investigator’s discretion.
  • 3. Subject able to provide written assent, if they have the ability to read and write, as determined by IRB/IEC/local requirements and Investigator’s discretion
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 560
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 50
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects who meet any of the following exclusion criteria are not to be enrolled in this Registry.
  • 1. Subject is currently receiving or plans to initiate a new course of hepatitis C therapyincluding any investigational drug or device during the course of the follow-up Registry.
  • 2. History of clinically-significant illness or any other major medical disorder that may interferewith the subject follow-up, assessments or compliance with the protocol.

研究者

相似试验

进行中(未招募)
1 期
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trial
EUCTR2014-004674-42-BEGilead Sciences, Inc.300
进行中(未招募)
1 期
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trial
EUCTR2014-004674-42-PLGilead Sciences, Inc560
进行中(未招募)
1 期
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trialChronic Hepatitis C virus infectionMedDRA version: 20.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-004674-42-ITGILEAD SCIENCES INCORPORATED300
进行中(未招募)
1 期
A long-term study to follow patients infected with chronic Hepatitis C who received a Gilead Hepatitis C treatment in a Gilead clinical trialChronic Hepatitis C virus infectionMedDRA version: 20.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestations
EUCTR2014-004674-42-DEGilead Sciences, Inc.560
进行中(未招募)
1 期
A long-term study to follow patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial.MedDRA version: 18.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsGenotype 1 Hepatitis C Virus InfectionMedDRA version: 18.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestations
EUCTR2011-000945-19-BEGilead Sciences Inc.10,470